Literature summary for 2.3.1.48 extracted from

Kadiyala, C.S.; Zheng, L.; Du, Y.; Yohannes, E.; Kao, H.Y.; Miyagi, M.; Kern, T.S.
Acetylation of retinal histones in diabetes increases inflammatory proteins: effects of minocycline and manipulation of histone acetyltransferase (HAT) and histone deacetylase (HDAC) (2012), J. Biol. Chem., 287, 25869-25880.

Search for more literature for 2.3.1.48

Application

Application	Comment	Organism
medicine	histone acetylation is significantly increased in retinas from diabetic rats, and this acetylation is inhibited in diabetics treated with minocycline. Both the acetylation and induction of the inflammatory proteins in elevated glucose levels are significantly inhibited by inhibitors of histone acetyltransferase, such as garcinol and antisense against the histone acetylase, p300, or activators of histone deacetylase, such as theophylline and resveratrol, and are increased by the histone deacetylase inhibitor, suberolylanilide hydroxamic acid. Hyperglycemia causes acetylation of retinal histones and probably other proteins and the acetylation contributes to the hyperglycemia-induced upregulation of proinflammatory proteins and thereby to the development of diabetic retinopathy	Rattus norvegicus

Inhibitors

Inhibitors	Comment	Organism	Structure
garcinol	both the acetylation and induction of the inflammatory proteins in elevated glucose levels are significantly inhibited by inhibitors of histone acetyltransferase, such as garcinol and antisense against the histone acetylase, p300	Rattus norvegicus
additional information	both the acetylation and induction of the inflammatory proteins in elevated glucose levels are significantly inhibited by inhibitors of histone acetyltransferase, such as garcinol and antisense against the histone acetylase, p300	Rattus norvegicus

Organism

Organism	UniProt	Comment	Textmining
Rattus norvegicus	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
retina	-	Rattus norvegicus	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)